Thursday, 30 June 2011 11:51

Quotient Bioresearch Signs Strategic Alliance With Cambridge Research Biochemicals

Quotient Bioresearch, a leading provider of early stage and specialist drug development services to pharmaceutical, biotechnology and medical device clients worldwide, has signed a strategic partnership agreement with Cambridge Research Biochemicals to provide a joint consultancy solution for tritium peptide labelling, offering significant cost and time savings to customers.

The partnership will see Quotient Bioresearch and Cambridge Research Biochemicals, the world’s second oldest peptide manufacturer, work together to supply both tritium radiolabelled and cold peptides as a package to a high quality with reliable delivery in a single shipment.

Cambridge Research Biochemicals has been making cold peptides for more than 30 years and Quotient scientists have been radiolabelling peptides with tritium for over 60 years. The new ‘one stop shop’ service will mean a more streamlined offering to customers with one contract and simpler pricing.

Stephen Lewinton, MD for Chemistry & Metabolism at Quotient Bioresearch, commented: “We have worked with Cambridge Research Biochemicals for a number of years; they are one of the most established and experienced suppliers in the peptide business. This formalised agreement will combine the expertise of both companies to give customers an improved service to obtain custom manufactured hot and cold peptides.”

Peptides which have been site-specifically labelled with tritium are ideal for use in receptor studies. Tritium labelling does not change the chemical structure of the peptide, producing labelled ligands with chemical and biological properties identical to those of the unlabelled molecule.

Emily Humphrys, Commercial Director at Cambridge Research Biochemicals, added: “Our strategic alliance with Quotient is a major benefit to our customers as it will provide a seamless operation for our Piquant™ Peptides (‘hot’) radiolabelled peptide offering.

“This marks a significant partnership for CRB with Quotient – the originators of Radiochemistry with their legacy of Amersham*.”

For further information about Quotient Bioresearch Ltd., visit the website at www.quotientbioresearch.com/chemistry-and-metabolismhttp://www.quotientbioresearch.com/bioanalytical-sciences. Further information about Cambridge Research Biochemicals Ltd. can be found at www.crbdiscovery.com.

*Amersham is a trademark of GE Healthcare



Read 4408 times

Leave a comment

Make sure you enter the (*) required information where indicated. HTML code is not allowed.

Want more? Visit...

Videos

  • ICON- Partnerships 12
    ICON- Partnerships 12 Steven Cutler, Group President of ICON discusses the launch of ICON's new acquisition of Firecrest at Partnerships in Clinical Trials 2012. Facing the continuing challenge of not only monitoring and…
    Read more...
  • ICON- Partnerships 12
    ICON- Partnerships 12 Steven Cutler, Group President of ICON discusses their exciting new partnership with Roche at Partnerships In Clinical Trials 2012. Medical imaging has always been a strong department within ICON. ICON…
    Read more...
  • ERT- Partnerships 12
    ERT- Partnerships 12 John Blakely, Executive Vice President and Chief Commercial Officer for ERT discusses the new trend in clinical research at Partnerships in Clinical Trials 2012 - the melding of objective and…
    Read more...
  • Chiltern- Partnerships 12
    Chiltern- Partnerships 12 Marcelo Piccirillo, Senior Clinical Research Physician for Chiltern, discusses new trends in gastrointestinal clinical development at Partnerships in Clinical Trials 2012. Current hot spots for clinical development in the field…
    Read more...
  • Blinded Diagnostics - Partnerships 12
    Blinded Diagnostics - Partnerships 12 Paul Savuto, President and CFO, and Steven Karrupan, CEO, from Blinded Diagnostics discuss Point of Care Technology at Partnerships in Clinical Trials 2012. Point of care (or decentralized testing) offers…
    Read more...
  • American Airlines - IQPC 2011
    American Airlines - IQPC 2011 American Airlines has globally launched a passive solutions that gives a new alternative to pharmaceutical manufacturers.
    Read more...

Podcasts